Glen French Joins EDAP’s Board of Directors

EDAP TMS SA has appointed Glen French to its Board of Directors.         

“We are pleased to welcome Glen to our Board of Directors,” EDAP TMS Interim Board Chairman Dr. Lance Willsey said. “Glen is a highly accomplished executive with extensive business and clinical expertise in the development of new medical devices and technology, and his presence on our Board of Directors will help guide our strategic decision-making as we establish Focal One as the world’s premier robotic HIFU technology platform.”        

French is a highly experienced public and private medical device and technology executive with more than 25 years of experience in developing and commercializing diagnostic and therapeutic products. He co-founded, built, and sold three medical device companies, and took a fourth company public.

For nearly a decade, French was the CEO of Pulmonx Corporation, which develops and markets minimally invasive technologies for diagnosing and treating patients with severe emphysema. During his tenure, the company executed four successful randomized controlled clinical trials, each published in peer-reviewed journals, leading to inclusion in global guidelines, and broad and attractive reimbursement. Also under his leadership, Pulmonx experienced more than 20% compound annual revenue growth, and in 2020 executed an initial public offering raising $218.5 million. 

Before Pulmonx, French was president of Pulmonary Endoscopy at Boston Scientific Corporation. Prior to Boston Scientific, he was CEO/co-founder of Asthmatx, where he led the company from concept, through clinical studies, product launch, and acquisition by Boston Scientific. Before Asthmatx, Glen was CEO/co-founder of Broncus Technologies (now Broncus Holding Corp.), and director/co-founder of NDO Surgical. Earlier in his career French held an array of sales and marketing management roles with C.R. Bard, Centocor, and American Hospital Supply Corporation.

French currently serves as a board member at Pulmonx Corporation, Myka Labs, and CoLabs Inc. He earned a bachelor of arts degree in history from Dartmouth College and an MBA in marketing and management from The Wharton School, University of Pennsylvania. 

“As a member of EDAP’s Board of Directors, I have the unique opportunity to join a company that is fundamentally changing the treatment paradigm of prostate cancer,” French stated. “Under its new senior leadership, EDAP has transformed itself into a high growth clinical and marketing organization that is now at the forefront of applying robotic HIFU technology to address significant unmet medical need in large patient populations. As Focal One continues to grow for the management of prostate cancer, I believe this technology can be successfully applied across several other therapeutic areas, including endometriosis, benign prostatic hyperplasia, and pancreatic cancer. I look forward to working with my fellow board members to help realize the full potential value of EDAP’s Focal One platform.”     

A leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP TMS introduced the Focal One in Europe and in the United States as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer.